Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued
Reference number: GID-TA10711
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603].
The company has informed NICE that it is withdrawing the evidence submission for this appraisal as it will be discontinuing the global clinical development programme for tanezumab following negative outcomes of both the FDA (Food and Drugs Administration) and EMA (European Medicines Agency) reviews of regulatory submissions.
Therefore, this topic will remain indefinitely suspended on the NICE work programme.